Cerus Corporation Reports 23% Revenue Growth to $59.9 Million in Q1 2026

Cerus Corporation reported its financial results for the first quarter of 2026, revealing a total revenue of $59.9 million, a 23% increase from $48.9 million in the same period last year. This growth was primarily driven by a 24% rise in product revenue, which reached $53.7 million, up from $43.2 million in the prior year. Government contract revenue also saw an 11% increase, totaling $6.2 million compared to $5.6 million in the previous year. The company reported a net loss of $1.6 million, significantly improved from a net loss of $7.7 million in the first quarter of 2025, resulting in a net loss per share of $0.01, compared to $0.04 in the prior year.

In terms of operational metrics, Cerus experienced a notable increase in cash and cash equivalents, which rose to $27.9 million from $20.0 million at the end of 2025. The company also reported a decrease in total liabilities, which fell to $154.6 million from $156.9 million at the end of the previous fiscal year. The reduction in liabilities was attributed to a decrease in non-current debt, which dropped to $32.4 million from $40.5 million. Additionally, the company’s employee headcount increased to 200, reflecting its ongoing investment in talent to support growth initiatives.

Strategically, Cerus has focused on expanding its market presence and enhancing its product offerings. The company continues to develop its INTERCEPT Blood System, which has received regulatory approvals in various regions, including the U.S. and Europe. The company is also working on the commercialization of its red blood cell system, which is currently in development and has not yet received marketing approval. Cerus has entered into agreements with the Biomedical Advanced Research and Development Authority (BARDA) and the U.S. Department of Defense (DoD) to support the development of its products, with BARDA agreements providing up to $185.5 million in funding.

Looking ahead, Cerus anticipates continued growth in product revenue driven by increased market acceptance of its INTERCEPT Blood System. However, the company also faces challenges, including potential decreases in government contract revenue as existing agreements expire. The company is actively managing its supply chain and production capabilities to meet anticipated demand, while also navigating the complexities of regulatory compliance and market dynamics. Cerus remains committed to achieving profitability in the future, although it acknowledges the uncertainties and risks associated with its ongoing development and commercialization efforts.